Merck Q3 EPS Beats Estimates and Company Raises Full-Year 2026 Guidance on Strong Pharmaceutical Pipeline Performance
Merck (MRK) Q3 2026 EPS beat analyst consensus estimates as the pharmaceutical giant raised full-year 2026 guidance, buying runway ahead of the 2028 Keytruda patent cliff
Key points
- Merck Q3 EPS beats, raises full-year 2026 guidance; strong near-term execution buys runway before 2028 Keytruda biosimilar competition
- Keytruda subcutaneous formulation and V116 pneumococcal vaccine are key pipeline catalysts for post-cliff revenue transition
- Merck IRA drug pricing impact disclosure is sector-wide multiple compression signal for large-cap US pharma investors
What’s your take on this? Join the discussion below.
Read the full analysis on market.news
🇺🇸 United States Stocks Breaking healthcare pharma